Enzo Biochem (NYSE:ENZ) issued its earnings results on Monday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.03), Bloomberg Earnings reports. The company had revenue of $26.95 million during the quarter, compared to analysts’ expectations of $27.35 million. Enzo Biochem had a negative net margin of 1.38% and a negative return on equity of 2.94%.
Enzo Biochem (NYSE ENZ) opened at $6.70 on Wednesday. Enzo Biochem has a 12 month low of $6.31 and a 12 month high of $12.04.
Separately, ValuEngine cut Enzo Biochem from a “hold” rating to a “sell” rating in a report on Thursday, March 1st.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2018/03/14/enzo-biochem-enz-issues-quarterly-earnings-results.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.